Download PDF
Deutsche Zeitschrift für Onkologie 2016; 48(03): 111-116
DOI: 10.1055/s-0042-113488
Forschung
© Karl F. Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Behandlung des Prostatakarzinoms mit Irreversibler Elektroporation (IRE)

Nina Klein
,
Enric Günther
,
Stefan Zapf
,
Rachid El-Idrissi
,
Sven Rachor
,
Michael Stehling
Further Information

Publication History

Publication Date:
05 October 2016 (online)

    Permissions and Reprints

Zusammenfassung

Die Irreversible Elektroporation, kurz IRE, hat sich in den letzten Jahren im Bereich der fokalen Ablation von Krebsgewebe in vielen medizinischen Einrichtungen weltweit als neuartige Behandlungsmethode etabliert. Auf Basis einer nicht-thermischen Technologie zerstört die IRE Zellen innerhalb des Behandlungsfeldes, während zellfreie Gewebsstrukturen erhalten bleiben. Sie ist eine schonende Alternative für die fokale Entfernung von Prostatakarzinomen, da Strukturen wie Nerven, Sphinkter und Rektum erhalten bleiben können. Deren Funktionalität und Erhalt ist häufig durch andere, radikalere Behandlungsmethoden gefährdet, was zu Impotenz und Inkontinenz führen kann. In Anbetracht der Tatsache, dass Prostatakrebs die zweithäufigste Krebsart bei Männern weltweit ist, hat der schonende Ansatz der IRE das Potenzial, die Prostatakarzinom-Therapie in der Medizin dauerhaft zu verändern.

Summary

Irreversible Electroporation (IRE), over the last few years, has established itself as a novel method in the field of focal cancer ablation in many medical institutions worldwide. Based on a non-thermal technology, IRE destroys cells whilst preserving non-cellular tissue elements within the treatment field. This property makes IRE a gentle alternative for focal treatments of prostate cancer, as structures such as nerves, sphincters and the rectum are preserved. The functionality and preservation of these structures are frequently compromised when prostate cancer is treated with other, more radical therapies, which can lead to impotence and incontinence. In view of the fact that prostate cancer is the second most common cancer in men worldwide, the gentle approach of IRE has the potential to permanently change the way prostate cancer is treated.

Schlüsselwörter

Irreversible Elektroporation - IRE - fokale Krebstherapie - Prostatakarzinom

Keywords

Irreversible electroporation - IRE - focal therapy - prostate cancer
 

  • Literatur

  • 1 Afshar-Oromieh A, Zechmann CM, Malcher A et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014; 41: 11-20 DOI: 10.1007/s00259-013-2525-5.
    CrossrefPubMedGoogle Scholar
  • 2 Alix-Panabières C, Pantel K. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. Cancer Discov 2016; 6(5): 479-491
    CrossrefPubMedGoogle Scholar
  • 3 Arena CB, Sano MB, Rossmeisl JH, Caldwell JL, Garcia PA, Rylander MN, Davalos RV. High-frequency irreversible electroporation (H-FIRE) for non-thermal ablation without muscle contraction. Biomed Eng Online 2011; Nov 21 10: 102 DOI: 10.1186/1475-925X-10-102.
    CrossrefPubMedGoogle Scholar
  • 4 Arena CB, Sano MB, Rylander MN, Davalos RV. Theoretical considerations of tissue electroporation with high-frequency bipolar pulses. IEEE Trans Biomed Eng 2011; 58(5): 1474-82 DOI: 10.1109/TBME.2010.2102021. Epub 2010 Dec 23.
    CrossrefPubMedGoogle Scholar
  • 5 Becker SM, Kuznetsov AV. Local Temperature Rises Influence In Vivo Electroporation Pore Development: A Numerical Stratum Corneum Lipid Phase Transition Model. J Biomech Eng 2007; 129: 712-21 DOI: 10.1115/1.2768380.
    CrossrefPubMedGoogle Scholar
  • 6 Bill-Axelson A, Holmberg L, Garmo H et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014; 370: 932-42 DOI: 10.1056/NEJMoa1311593.
    CrossrefPubMedGoogle Scholar
  • 7 Bozzini G, Colin P, Nevoux P, Villers A, Mordon S, Betrouni N. Focal therapy of prostate cancer: energies and procedures. Urol Oncol 2013; 31(2): 155-167
    CrossrefPubMedGoogle Scholar
  • 8 Brausi MA, Giliberto GL, Simonini GL et al. 960 Irreversible Electroporation (Ire), a Novel Technique for Focal Ablation of Prostate Cancer (Pca): Results of a Interim Pilot Safety Study in Low Risk Patients With Pca. Eur Urol Suppl 2011; March 10(2): 300-300 DOI: 10.1016/S1569-9056(11)60942-1.
    PubMedGoogle Scholar
  • 9 Bulvik BE, Rozenblum N, Gourevich S et al. Irreversible electroporation versus radiofrequency ablation: a comparison of local and systemic effects in a small-animal model. Radiology 2016; 280(2): 413-24
    CrossrefPubMedGoogle Scholar
  • 10 Choi JW, Lu DS, Osuagwu F, Raman S, Lassman C. Assessment of chronological effects of irreversible electroporation on hilar bile ducts in a porcine model. Cardiovasc Intervent Radiol 2014; 37: 224-30 DOI: 10.1007/s00270-013-0731-y.
    CrossrefPubMedGoogle Scholar
  • 11 Davalos RV, Mir LM, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng 2005; 33(2): 223-31
    CrossrefPubMedGoogle Scholar
  • 12 Davalos RV, Bhonsle S, Neal RE. Implications and considerations of thermal effects when applying irreversible electroporation tissue ablation therapy. Prostate 2015; 75(10): 1114-8 DOI: 10.1002/pros.22986.
    CrossrefPubMedGoogle Scholar
  • 13 Fütterer JJ, Briganti A, De Visschere P, Emberton M et al. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. Eur Urol 2015; 68(6): 1045-53 DOI: 10.1016/ j.eururo.2015.01.013. Epub 2015 Feb 2
    CrossrefPubMedGoogle Scholar
  • 14 van Gemert MJC, Wagstaff PGK, de Bruin DM et al. Irreversible Electroporation: Just Another Form of Thermal Therapy?. Prostate 2015; 75(3): 332-5 DOI: 10.1002/pros.22913. Epub 2014 Oct 18
    CrossrefPubMedGoogle Scholar
  • 15 Gold B, Cankovic M, Furtado LV, Meier F, Gocke CD. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the Association for Molecular Pathology. J Mol Diagn 2015; 17(3): 209-24
    CrossrefPubMedGoogle Scholar
  • 16 Haberl S, Miklavcic D, Sersa G, Frey W, Rubinsky B. Cell membrane electroporation–Part 2: the applications. IEEE Electrical Insulation Magazine 2013; 29(1): 29-37
    PubMedGoogle Scholar
  • 17 Han M, Partin AW, Zahurak M et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169: 517-23 DOI: 10.1097/01.ju.0000045749.90353.c7.
    CrossrefPubMedGoogle Scholar
  • 18 Jiang C, Qin Z, Bischof J. Membrane-targeting approaches for enhanced cancer cell destruction with irreversible electroporation. Ann Biomed Eng 2014; 42: 193-204 DOI: 10.1007/s10439–013–0882–7.
    CrossrefPubMedGoogle Scholar
  • 19 Kasivisvanathan V, Emberton M, Ahmed HU. Focal therapy for prostate cancer: rationale and treatment opportunities. Clin Oncol (R Coll Radiol) 2013; 25: 461-73 DOI: 10.1016/j.clon.2013.05.002.
    CrossrefPubMedGoogle Scholar
  • 20 Kitajima K, Murphy RC, Nathan MA et al. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-Choline PET/CT with pelvic multiparametric MR imaging with endorectal coil. J Nucl Med 2014; 55: 223-232 DOI: 10.2967/jnumed. 113.123018.
    CrossrefPubMedGoogle Scholar
  • 21 Klein N, Guenther E, Zapf S, ElIdrissi R, Mikus P, Rubinsky B, Stehling M. Prostate cancer treatment with Irreversible Electroporation. The Global Congress on Prostate Cancer, Vienna, June 29th – July 1st,. 2016
    PubMedGoogle Scholar
  • 22 Kotnik T, Pucihar G, Rebersek M, Miklavcic D, Mir LM. Role of pulse shape in cell membrane electropermeabilization. Biochim Biophys Acta 2003; 1614(2): 193-200 DOI: 10.1016/S0005–2736(03)00173–1.
    CrossrefPubMedGoogle Scholar
  • 23 Li W, Fan Q, Ji Z et al. The effects of irreversible electroporation (IRE) on nerves. PLoS One 2011; Apr 14 6(4): e18831 DOI: 10.1371/journal.pone.0018831.
    CrossrefPubMedGoogle Scholar
  • 24 Liu W, Laitinen S, Khan S et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009; 15(5): 559-65
    CrossrefPubMedGoogle Scholar
  • 25 Maor E, Ivorra A, Leor J, Rubinsky B. The effect of irreversible electroporation on blood vessels. Technol Cancer Res Treat 2007; 6(4): 307-12
    CrossrefPubMedGoogle Scholar
  • 26 Maurer T, Eiber M, Schwaiger M. Gschwend JE Current use of PSMA–PET in prostate cancer management. Nat Rev Urol 2016; 13(4): 226-35 DOI: 10.1038/nrurol.2016.26. Epub 2016 Feb 23
    CrossrefPubMedGoogle Scholar
  • 27 Mir LM, Belehradek M, Domenge C, Orlowski S, Poddevin B, Belehradek Jr J, Schwaab G, Luboinski B, Paoletti C. Electrochemotherapy, a new antitumor treatment: first clinical trial. C R Acad Sci III Sciences de la vie 1991; 313(13): 613-8
    PubMedGoogle Scholar
  • 28 Neal RE, Kavnoudias H, Rosenfeldt F, Ou R, Marron J, Davalos RV, Thomson KR. In Vivo Validation of Irreversible Electroporation Electric Field Threshold for Prostate Tissue. ASME 2013 Summer Bioengineering Conference. American Society of Mechanical Engineers. 2013
    PubMedGoogle Scholar
  • 29 Neal RE, Rossmeisl JH, Robertson JL, Arena CB, Davis EM, Singh RN, Stallings J, Davalos RV. Improved local and systemic anti-tumor efficacy for irreversible electroporation in immunocompetent versus immunodeficient mice. PloS One 2013; May 24 8(5): e64559
    CrossrefPubMedGoogle Scholar
  • 30 Ongaro A, Pellati A, Caruso A, Battista M, De Terlizzi F, De Mattei M, Fini M. Identification of in vitro electropermeabilization equivalent pulse protocols. Technol Cancer Res Treat 2011; 10: 465-73 DOI: 10.7785/tcrt.2012.500223.
    CrossrefPubMedGoogle Scholar
  • 31 Onik G, Mikus P, Rubinsky B. Irreversible electroporation: implications for prostate ablation. Technol Cancer Res Treat 2007; 6(4): 295-300
    CrossrefPubMedGoogle Scholar
  • 32 Onik G, Miessau M, Bostwick DG. Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol 2009; 27: 4321-6 DOI: 10.1200/JCO.2008.20.3497.
    CrossrefPubMedGoogle Scholar
  • 33 Onik G, Rubinsky B. Irreversible Electroporation: First Patient Experience Focal Therapy of Prostate Cancer. In: Irreversible Electroporation. Berlin, Heidelberg: Springer; 2010. 235-247
    Google Scholar
  • 34 Onik G. Focal Therapy for Prostate Cancer Using Irreversible Electroporation. In: Image Guided Prostate Cancer Treatments. Berlin, Heidelberg: Springer; 2014. 235-241
    Google Scholar
  • 35 Panebianco V, Barchetti F, Sciarra A, Ciardi A, Indino EL, Papalia R, Gallucci M, Tombolini V, Gentile V, Catalano C. Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study. Urol Oncol 2015; 33(1): 17.e1-7 DOI: 10.1016/j.urolonc.2014.09.013. Epub 2014 Nov 11
    CrossrefPubMedGoogle Scholar
  • 36 Parker C, Muston D, Melia J, Moss S, Dearnaley D. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 2006; 94: 1361-8 DOI: 10.1038/sj.bjc.6603105.
    CrossrefPubMedGoogle Scholar
  • 37 Rubinsky B. Irreversible electroporation in medicine. Technol Cancer Res Treat 2007; 6: 255-60 DOI: 10.1007/978–3-642–05420–4.
    CrossrefPubMedGoogle Scholar
  • 38 Rubinsky B, Onik G, Mikus P. Irreversible electroporation: a new ablation modality -- clinical implications. Technol Cancer Res Treat 2007; 6: 37-48 DOI: 10.1177/153303460700600106.
    CrossrefPubMedGoogle Scholar
  • 39 Rubinsky J, Onik G, Mikus P, Rubinsky B. Optimal parameters for the destruction of prostate cancer using irreversible electroporation. J Urol 2008; 180: 2668-74 DOI: 10.1016/j.juro.2008.08.003.
    CrossrefPubMedGoogle Scholar
  • 40 Savic LJ, Chapiro J, Hamm B, Gebauer B, Collettini F. Irreversible Electroporation in Interventional Oncology: Where We Stand and Where We Go. RöFo 2016; 188(8): 735-45 DOI: 10.1055/ s-0042–104203. Epub 2016 Apr 13.
    PubMedGoogle Scholar
  • 41 Scheltema MJ, van den Bos W, de Bruin DM, Wijkstra H, Laguna MP, de Reijke TM, de la Rosette JJ. Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial. BMC Cancer 2016; May 5 16: 299 DOI: 10.1186/s12885–016–2332-z.
    CrossrefPubMedGoogle Scholar
  • 42 Schoellnast H, Monette S, Ezell PC, Deodhar A, Maybody M, Erinjeri JP, Stubblefield MD, Single GW, Hamilton WC, Solomon SB. Acute and subacute effects of irreversible electroporation on nerves: experimental study in a pig model. Radiology 2011; 260(2): 421-7 DOI: 10.1148/radiol.11103505. Epub 2011 Jun 3
    CrossrefPubMedGoogle Scholar
  • 43 Schoellnast H, Monette S, Ezell PC, Single G, Maybody M, Weiser MR, Fong Y, Solomon SB. Irreversible electroporation adjacent to the rectum: evaluation of pathological effects in a pig model. Cardiovasc Intervent Radiol 2013; 36: 213-20 DOI: 10.1007/s00270–012–0393–1. Epub 2012 May 5
    CrossrefPubMedGoogle Scholar
  • 44 Schoellnast H, Monette S, Ezell PC, Maybody M, Erinjeri JP, Stubblefield MD, Single G, Solomon SB. The delayed effects of irreversible electroporation ablation on nerves. Eur Radiol 2013; 23: 375-80 DOI: 10.1007/s00330–012–2610–3.
    CrossrefPubMedGoogle Scholar
  • 45 Ting F, Tran M, Böhm M, Siriwardana A, Van Leeuwen PJ, Haynes AM, Delprado W, Shnier R, Stricker PD. Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control. Prostate Cancer Prostatic Dis 2016; 19(1): 46-52 DOI: 10.1038/pcan.2015.47. Epub 2015 Oct 13.
    CrossrefPubMedGoogle Scholar
  • 46 Valerio M, Ahmed HU, Emberton M, Lawrentschuk N, Lazzeri M, Montironi R, Nguyen PL, Trachtenberg J, Polascik TJ. The role of focal therapy in the management of localised prostate cancer: a systematic review. Eur Urol 2014; 66: 732-51 DOI: 10.1016/ j.eururo.2013.05.048.
    CrossrefPubMedGoogle Scholar
  • 47 Valerio M, Dickinson L, Ali A, Ramachandran N, Donaldson I, Freeman A, Ahmed HU, Emberton M. A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT). Contemp Clin Trials 2014; 39(1): 57-65
    CrossrefPubMedGoogle Scholar
  • 48 Valerio M, Stricker PD, Ahmed HU, Dickinson L, Ponsky L, Shnier R, Allen C, Emberton M. Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer. Prostate Cancer Prostatic Dis 2014; 17(4): 343-7
    CrossrefPubMedGoogle Scholar
  • 49 Valerio M, Ahmed HU, Emberton M. Focal therapy of prostate cancer using irreversible electroporation. Tech Vasc Interv Radiol 2015; 18(3): 147-52
    CrossrefPubMedGoogle Scholar
  • 50 van den Bos W, Jurhill RR, de Bruin DM et al. Histopathological outcomes after irreversible electroporation in prostate cancer; Results of an ablate-and-resect study. J Urol 2016; 196(2): 552-9 DOI: 10.1016/j.juro.2016.02.2977.
    CrossrefPubMedGoogle Scholar
  • 51 Wilt TJ, Brawer MK, Jones KM. et aI. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367(3): 203-13 DOI: 10.1056/NEJMoa 1113162.
    CrossrefPubMedGoogle Scholar